Current Report Filing (8-k)
May 25 2021 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 23, 2021
ORAMED PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State or Other Jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification No.)
|
1185 Avenue of the Americas, Third Floor, New York, New York
|
|
10036
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
844-967-2633
(Registrant’s telephone number, including
area code)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.012
|
|
ORMP
|
|
The Nasdaq Capital Market, Tel Aviv Stock Exchange
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 23, 2021, Oramed Pharmaceuticals
Inc. (the “Company”) appointed David Silberman, 37, to serve as Chief Financial Officer, Treasurer and Secretary, effective
July 5, 2021. Prior to his appointment, from April 2018 until May 2021, Mr. Silberman served as a Corporate Financial Planning and Analysis
associate director and director at Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, committed to helping patients
around the world to access affordable medicines and benefit from innovations to improve their health. From 2014 to 2018, Mr. Silberman
served as Global Internal Audit Senior Manager at Teva Pharmaceutical Industries Ltd.. From 2009 to 2014, Mr. Silberman provided internal
audit and risk management services in the advisory department of Grant Thornton Fahn Kanne Control Management. From January 2009 until
June 2009, Mr. Silberman worked in the audit department of KPMG, a certified public accounting firm. Mr. Silberman holds a DCG and a DSCG
degrees from the French Ministry of higher study and research and is a certified public accountant in Israel.
Mr. Silberman will be employed
by the Company pursuant to an employment agreement with the Company’s wholly-owned Israeli subsidiary, Oramed Ltd. Mr. Silberman’s
gross monthly salary will be NIS 37,500, and he will be provided with a company car. Mr. Silberman will be eligible for bonuses and equity
grants in amounts to be determined at the discretion of the Company’s Board of Directors and the Compensation Committee of the Company’s
Board of Directors, as applicable. In connection with Mr. Silberman’s appointment, the Company expects to enter into its standard
indemnification agreement with Mr. Silberman, on substantially the same terms as the indemnification agreements previously entered into
between the Company and each of its directors and executive officers. Mr. Silberman is not a party to any transactions that are disclosable
under Item 404 of Regulation S-K.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS INC.
|
|
|
|
By:
|
/s/ Nadav Kidron
|
|
Name:
|
Nadav Kidron
|
|
Title:
|
President and CEO
|
|
|
|
May 25, 2021
|
|
|
2
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024